Bristol Myers Squibb Expands Nvidia AI Partnership for Drug Discovery

Bristol Myers Squibb faces structural headwinds: revenue and earnings growth have been weak due to patent exclusivity losses, and the company confronts major patent cliffs for two of its most important drugs—Eliquis and Opdivo. The pharmaceutical industry's core challenge is that drug development remains slow and expensive, creating a natural opening for artificial intelligence to reduce both time and cost. By deploying Nvidia's next-generation DGX SuperPOD supercomputer, Bristol Myers is betting that AI can materially improve its competitive position. The company's management has already flagged that earlier AI efforts are bearing fruit, which suggests the new investment is not speculative but incremental to a working strategy.

The leverage for Bristol Myers is substantial because the company operates dozens of active pipeline programs. Even modest AI-driven improvements—cutting development time or cost by just 1%—would compound across that portfolio to yield material business impact. The company is also developing newer medicines like milvexian and pumitamig that could help offset revenue loss as older drugs lose patent protection, and Bristol Myers has won approval for Opdivo Qvantig, a longer-protected formulation of its existing cancer drug. The stock trades at 9.7x forward earnings, below the healthcare sector average of 18.1x, and pays a solid dividend, suggesting valuation may offer some margin of safety alongside the AI upside.